

## **REQUIREMENT FOR INFORMATION**

1. Applicant and the assignee of this application are required under 37 CFR 1.105 to provide the following information that the examiner has determined is reasonably necessary to the examination of this application.
2. A search of the prior art on 11/24/2008 yielded an abstract for a presentation by Toki *et al.* at the 223rd ACS National Meeting in Orlando, FL on April 7-11 titled: "Cures and regressions of established tumor xenografts with monoclonal antibody auristatin" (CAS 2002:190266). The abstract states that Aerostation E was linked to several mAbs, including BR96 and SGN-30 through novel linkers that released fully active drug under mildly acidic conditions or in the presence of intracellular proteases. This information suggests that the subject matter of the presentation was at least closely related to, and may read on, the instantly claimed invention. A copy of the complete presentation is required to determine if it constitutes prior art under 35 U.S.C. 102(a).
3. In response to this requirement, please provide a copy of the complete presentation given by Toki *et al.* at the 223rd ACS National Meeting in Orlando, FL on April 7-11.
4. The fee and certification requirements of 37 CFR 1.97 are waived for those documents submitted in reply to this requirement. This waiver extends only to those documents within the scope of this requirement under 37 CFR 1.105 that are included in the applicant's first complete communication responding to this requirement. Any supplemental replies subsequent to the first communication responding to this requirement and any information disclosures beyond the scope of this requirement under 37 CFR 1.105 are subject to the fee and certification requirements of 37 CFR 1.97.

5. The applicant is reminded that the reply to this requirement must be made with candor and good faith under 37 CFR 1.56. Where the applicant does not have or cannot readily obtain an item of required information, a statement that the item is unknown or cannot be readily obtained may be accepted as a complete reply to the requirement for that item.

6. This requirement is subject to the provisions of 37 CFR 1.134, 1.135 and 1.136 and has a shortened statutory period of 2 months. EXTENSIONS OF THIS TIME PERIOD MAY BE GRANTED UNDER 37 CFR 1.136(a).

7. Any inquiry concerning this communication or earlier communications from the examiner should be directed to Christina Marchetti Bradley whose telephone number is (571)272-9044. The examiner can normally be reached on Monday-Thursday, 9:00 A.M. to 3:00 P.M.

8. If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Cecilia Tsang can be reached on (571) 272-0562. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

9. Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see <http://pair-direct.uspto.gov>. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.

/Cecilia Tsang/  
Supervisory Patent Examiner, Art Unit 1654

/Christina Marchetti Bradley/  
Examiner, Art Unit 1654